K. Battmer, R. Jacobs, J. Casper, H. Diedrich, J. Schubert, J. Kühl, and H. Poliwoda. 1997. Transplantation of Allogeneic Peripheral Blood Progenitor Cells Alone or in Addition to Bone Marrow. In Acute [...] J. Kadar, K. Battmer, R. Jacobs, H. Diedrich, J. Schubert, J. Kühl, and H. Poliwoda. 1995. Transplantation of allogeneic peripheral blood progenitor cells alone or in addition to bone marrow. In Acute
type of transplant, pre-existing conditions, medication and infections are understood, the better prevention and treatment can be carried out in practice. Objectives With the help of the transplant cohort [...] insights and continuous improvements in the treatment of transplant patients. Collected data and samples An essential component of the transplant cohort is the cohort database, which is operated by the [...] into the individual infection risk of transplant patients. This includes information on pre-existing conditions, existing infections, the course of the transplant, medication and infectious events that
hypertension (PAH), a lung transplant is sometimes the only remaining treatment option. However, there is a substantial risk of various complications following lung transplantation. In addition to direct toxic [...] of COVID-19 disease and its late effects as well as the pathophysiology of changes after lung transplantation. The Lung Research Group is characterized by a national and international network with numerous [...] median 5-year survival is about 30%. A curative therapy is not yet available, leaving only lung transplantation as a last resort in the final stage of the disease. Histomorphological signs of advanced PAH
limitation, euthanasia, termination of pregnancy after prenatal diagnosis, organ donation and transplantation, clinical ethics counseling) and research ethics (stem cell research, cloning, Ethics Committees)
children with all types of malignant childhood diseases, but also performs all types of stem cell transplants. The following three pillars illustrate the main areas of our clinical work. About clinical trials
surrounding the topic of cell therapies, such as "Can these therapies offer an alternative to organ transplantation?", "How is research using patient stem cells regulated in terms of ethics and the law?", "Why
logy working group focuses its research on immunological issues in autologous kidneys, kidney transplants and kidney tumors in numerous own and collaborative projects. Among other things, we use digital
issues, nor is there a body that represents us or offers such opportunities. Risk management in transplantation - impact of the new Tissue Act for physicians and hospitals September 04, 2008 / 14:00 - 18:00
together with the Clinical Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation and the Institute of Transfusion Medicine organizes the block practical course "Clinical Chemistry
Tumor Center and the Clinical Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation. Contact person: Prof. Dr. med. Thomas Skripuletz Dr. med. Philipp Schwenkenbecher Dr. med. Nora